Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:19 AM
Ignite Modification Date: 2025-12-25 @ 3:19 AM
NCT ID: NCT02543905
Eligibility Criteria: Inclusion Criteria: Either: 1. Men of any ethnicity with a positive family history of PrCa defined as: * Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at \<70 years * Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at \<70 years * Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age Or 2. Men of black African or black African-Caribbean ancestry defined as: Both parents and all 4 grandparents being of either black African or black African-Caribbean ancestry. Or 3. Men of any ethnicity with a genetic predisposition to having prostate cancer e.g., being known to have inherited a gene mutation that increases risk of prostate cancer (e.g. BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol); and/or being known to have a high polygenic risk score (PRS) (defined as being in the top tenth percentile prior to enrolment). * Age 40- 69 years * WHO performance status 0-2 * Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow up schedule. Exclusion Criteria: * Previous cancer with a life expectancy of less than five years. * Previous PrCa * Negative biopsy within one year before recruitment * Co-morbidities making prostate biopsy risk unacceptable (anticoagulants or antiplatelet medication including Warfarin, Clopidogrel, Apixaban, Dabigatran or other NOAC (Novel Oral Anti-Coagulant); poorly controlled diabetes, cardiovascular/respiratory disease, immunosuppressive medication or splenectomy) * Men with body mass index (BMI) 40 and above. * Men with BMI 35 and above plus other co-morbidities. * Contraindications to having an MRI (non-MRI compliant pacemakers, aneurysm clips, metallic cardiac valve/stent, Ventriculo-Peritoneal (VP) shunt, cochlear implant, neurotransmitter, metallic foreign bodies in eye(s), other metalwork, claustrophobia) * Any significant psychological conditions that may be worsened or exacerbated by participation in the study
Healthy Volunteers: True
Sex: MALE
Minimum Age: 40 Years
Maximum Age: 69 Years
Study: NCT02543905
Study Brief:
Protocol Section: NCT02543905